Home › Tricuspid Valve Insufficiency › NCT07321899

Transcatheter Tricuspid Valve Replacement With the Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System in Severe Tricuspid Regurgitation

Transcatheter Tricuspid Valve Replacement Using the Medtronic Intrepid™ TTVR System in Patients With Severe Symptomatic Tricuspid Regurgitation - PATHFINDER

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Age ≥18 years at the time of consent.
* Severe symptomatic tricuspid regurgitation (TR) despite optimal medical therapy (OMT).
* Local site multidisciplinary heart team experienced in tricuspid valve therapies agrees that the subject is appropriate for TTVR.

Exclusion Criteria:

* Any tricuspid device currently in place.
* Anatomic contraindications.
* Need for emergent or urgent surgery.
* Left ventricular ejection fraction \<25%.

About the study

This clinical trial evaluates the safety and effectiveness of the Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System in symptomatic patients with severe or greater tricuspid regurgitation.

What is being tested

• Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System (device)
• Edwards EVOQUE Tricuspid Valve Replacement (TTVR) System (device)

Sponsor: Medtronic Cardiovascular · Participants: 1,186 · Started: Sep 11, 2026

Contact the study team

• Amber St Martin · Phone: 612-380-5637

Official record on ClinicalTrials.gov — NCT07321899

Locations in the U.S.

Conditions

• Tricuspid Valve Insufficiency
• Heart Valve Diseases

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.